| 3.685 -0.045 (-1.2%) | 04-24 10:14 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 4.79 | 1-year : | 5.41 |
| Resists | First : | 4.1 | Second : | 4.63 |
| Pivot price | 3.72 |
|||
| Supports | First : | 3.25 | Second : | 2.7 |
| MAs | MA(5) : | 3.58  |
MA(20) : | 3.77 |
| MA(100) : | 3.6 |
MA(250) : | 2.58 |
|
| MACD | MACD : | -0.2 |
Signal : | -0.2 |
| %K %D | K(14,3) : | 35.1 |
D(3) : | 25.3 |
| RSI | RSI(14): 46.8 |
|||
| 52-week | High : | 5.21 | Low : | 1.29 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ SMMT ] has closed above bottom band by 45.5%. Bollinger Bands are 28.4% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 3.92 - 3.95 | 3.95 - 3.97 |
| Low: | 3.43 - 3.45 | 3.45 - 3.48 |
| Close: | 3.69 - 3.73 | 3.73 - 3.77 |
Summit Therapeutics Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat infectious diseases in the United States and Latin America. It conducts clinical programs focusing on Clostridioides difficile infection (CDI). The company's lead product candidate is ridinilazole, an orally administered small molecule antibiotic that is in Phase III clinical trials for the treatment of CDI. It also offers SMT-738, for combating multidrug resistant infections primarily carbapenem-resistant Enterobacteriaceae infections; and DDS-04 series for the potential treatment of infections caused by the Enterobacteriaceae. The company was founded in 2003 and is based in Cambridge, Massachusetts.
Tue, 23 Apr 2024
Summit Therapeutics (NASDAQ:SMMT) Shares Up 10.6% - MarketBeat
Sat, 20 Apr 2024
Summit Therapeutics (SMMT) Catches Eye: Stock Jumps 8.8% - Yahoo Movies Canada
Wed, 03 Apr 2024
Summit Therapeutics (SMMT) Announces CFO Resignation - StreetInsider.com
Wed, 03 Apr 2024
Commit To Buy Summit Therapeutics At $3, Earn 24.6% Annualized Using Options - Nasdaq
Tue, 26 Mar 2024
Analysts Eye Summit Therapeutics' Ivonescimab As Potential Challenger To Merck's Keytruda in Lung Cancer Treatment - Markets Insider
Mon, 11 Mar 2024
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Summit Therapeutics Inc ... - PR Newswire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 702 (M) |
| Shares Float | 83 (M) |
| Held by Insiders | 88.1 (%) |
| Held by Institutions | 4.8 (%) |
| Shares Short | 21,810 (K) |
| Shares Short P.Month | 15,950 (K) |
| EPS | -1 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.1 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -12.8 % |
| Return on Equity (ttm) | -601.9 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -0.13 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -77 (M) |
| Levered Free Cash Flow | -220 (M) |
| PE Ratio | -3.73 |
| PEG Ratio | 0 |
| Price to Book value | 33.5 |
| Price to Sales | 0 |
| Price to Cash Flow | -33.69 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|